Catalyst Capital Advisors LLC Satsuma Pharmaceuticals, Inc. Transaction History

Catalyst Capital Advisors LLC

  • $4.41 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 06, 2020
SELL
$9.32 - $19.68 $3,103 - $6,553
-333 Closed
0 $0
Q3 2019

Nov 05, 2019
BUY
$14.98 - $16.9 $4,988 - $5,627
333 New
333 $5,000

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Catalyst Capital Advisors LLC Portfolio

Follow Catalyst Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Capital Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email